# Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

> **NCT03592199** · PHASE2 · UNKNOWN · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 7 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03592199
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-11
- **Primary completion:** 2019-12-11
- **Final completion:** 2022-12-11
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03592199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03592199, "Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03592199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*